| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_502b043da975a2ae3d3a08f1b6e39933 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-5412
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2871 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6869 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate |
2021-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4cbbd9200526612739b503e869886923
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d677cf2f98f3cca49fb79f9338886d06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1f81f5cb887e8710c79fbfae60b2252
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_109226fd3d2c59de944270f92ebedb85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9094dbca52d70ea1ad1ccfccf8587854
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_550f6d211673943b97816b7af5e7dd49
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca0d1241f6daad6906be29a73ba46512
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78d47a6fb48bda7c22b6964d697c2537
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a85afb21c232f01efbb4537880df8ab |
| publicationDate |
2021-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-113588968-A |
| titleOfInvention |
IL-6 in NDSEV as a marker for diagnosis and/or treatment of subarachnoid hemorrhage |
| abstract |
The invention discloses IL-6 in a brain-derived vesicle (NDSEV) as a marker for diagnosing and/or treating subarachnoid hemorrhage, and IL-6 in the NDSEV as a marker for diagnosing and/or treating subarachnoid hemorrhage. The application of the antibody for detecting IL-6 in the NDSEV in the preparation of a kit for diagnosing subarachnoid hemorrhage. The test of the invention proves that: IL-6 levels in plasma NDSEV of aSAH patients were significantly different compared to normal. High levels of NDSEV IL-6 are positively correlated with patient severity and prognosis. These results indicate that high levels of the neuroinflammatory cascade are present in aah patients. IL-6 in NDSEV may be a potential biomarker for predicting disease progression in aSAH patients and may be used in the future to assess prognosis for this disease. |
| priorityDate |
2021-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |